This result is not nearly as sluggish as the market response suggests.
They booked significant costs, either for future growth (14% R&D increase and new product support +>increased 15% increase in staffing), or none-offs ($12m donation of product and $65m unfavourable forex move, taken above the line).
Most companies would have capitalised some of these expenses, but not CSL; they just expense them outright. Very conservative accounting for profits, which I like.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$263.95 |
Change
8.640(3.38%) |
Mkt cap ! $127.8B | |||
| Open | High | Low | Value | Volume |
| $258.12 | $264.81 | $257.91 | $311.0M | 1.182M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 833 | $263.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $263.98 | 30529 | 2 |
View Market Depth
| Last trade - 16.10pm 22/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |